Adverum Biotechnologies Receives Orphan Drug Designation for Hereditary Angioedema Gene Therapy Candidate

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced on 8/24/18 that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADVM-053, a preclinical gene therapy candidate being investigated as a potential single‑administration treatment which has the potential to provide sustained levels of the C1 esterase inhibitor (“C1EI”) protein.